Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5861097 | 0.93 | KMT2A (0.50) | CYP1A2KMT2ACYP3A4CYP2C19TDP1 | |
| SCHEMBL5861107 | 0.93 | KMT2A (0.50) | CYP1A2KMT2ACYP3A4CYP2C19TDP1 | |
| SCHEMBL11948863 | 0.93 | KMT2A (0.50) | CYP1A2KMT2ACYP3A4CYP2C19TDP1 | |
| SCHEMBL13923800 | 0.93 | KMT2A (0.50) | CYP1A2KMT2ACYP3A4CYP2C19TDP1 | |
| SCHEMBL6248687 | 0.90 | CYP1A2 (0.51) | CYP1A2KMT2ACYP3A4CYP2C19TDP1 | |
| SCHEMBL6248685 | 0.90 | CYP1A2 (0.51) | CYP1A2KMT2ACYP3A4CYP2C19TDP1 | |
| SCHEMBL6054595 | 0.90 | CYP1A2 (0.51) | CYP1A2KMT2ACYP3A4CYP2C19TDP1 | |
| SCHEMBL6054594 | 0.90 | CYP1A2 (0.51) | CYP1A2KMT2ACYP3A4CYP2C19TDP1 | |
| SCHEMBL13766508 | 0.88 | CYP1A2 (0.54) | CYP1A2CYP3A4CYP2C19TDP1GLA | |
| SCHEMBL25860710 | 0.84 | TDP1 (0.46) | CYP1A2KMT2ACYP3A4CYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077989-A1 | CYCLIC IMIDATE LIGANDS | UNIVERSITEIT GENT (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077989-A1 | CYCLIC IMIDATE LIGANDS | IDH2, CYCS, NAPRT | CYP1A2 2197/4885KMT2A 2204/4885CYP3A4 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.